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Abstract
Background: Pancreatoduodenectomy (PD) is a technically challenging operation characterized by
numerous management decisions.
Objective: This study was designed to test the hypothesis that there is significant variation in the con-
temporary global practice of PD.
Methods: A survey with native-language translation was distributed to members of 22 international
gastrointestinal surgical societies. Practice patterns and surgical decision making for PD were
assessed. Regions were categorized as North America, South/Central America, Asia/Australia, and
Europe/Africa/Middle East.
Results: Surveys were completed by 897 surgeons, representing six continents and eight languages.
The median age and length of experience of respondents were 45 years and 13 years, respectively. In
2013, surgeons performed a median of 12 PDs and reported a median career total of 80 PDs; only
53.8% of respondents had surpassed the number of PDs considered necessary to surmount the learn-
ing curve (>60). Significant regional differences were observed in annual and career PD volumes
(P < 0.001). Only 3.7% of respondents practised pancreas surgery exclusively, but 54.8% performed
only hepatopancreatobiliary surgery. Worldwide, the preferred form of anastomotic reconstruction was
pancreatojejunostomy (88.7%). Regional variability was evident in terms of anastomotic/suture tech-
nique, stent use and drain use (including type and number), as well as in the use of octreotide, sea-
lants and autologous patches (P < 0.02 for all).
Conclusions: Globally, there is significant variability in the practice of PD. Many of these choices
contrast with established randomized evidence and may contribute to variance in outcomes.
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Introduction
Pancreatoduodenectomy (PD) is a technically challenging oper-
ation characterized by numerous management decisions. Oper-
ative options refer to the type of anastomotic reconstruction,
as well as the use of trans-anastomotic stents, biological
sealants, autologous tissue patches and drains. Additionally,
surgeons are confronted with management choices concerning
the administration of prophylactic somatostatin analogues and
the duration of drainage. Many of these practices have been
scrutinized in randomized controlled trials (RCTs), which have
established Level I evidence in the contemporary surgical litera-
ture.1–6
The International Study Group on Pancreatic Surgery
(ISGPS) has served as the foundation for many of these inves-
tigations. Through a rigorous consensus process, the ISGPS
established standardized definitions for many post-pancreatec-
tomy complications.7–9 In addition to improving the quality
of comparative research, these definitions have facilitated
unbiased comparisons of intraoperative techniques and man-
agement decisions.
This study explores the hypothesis that there is significant
variation in the contemporary global practice of PD. The pri-
mary aims of this study are two-fold. The first is to establish
global benchmarks for the surgical experience of surgeons who
This study was presented at the Annual Meeting of the AHPBA, 11-15
March 2015, Miami, Florida.
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practise PD; results will be compared with published cut-offs
relating to the PD learning curve and high-volume status. The
second aim is to report current worldwide practice patterns in
surgeons who perform PD. Collective responses will be
compared with best clinical practice established by contempo-
rary Level I evidence. Trends will be assessed to determine if
there is regional bias in the implementation of best clinical
practices.
Materials and methods
This study was approved by the institutional review board
(IRB) at the Hospital of the University of Pennsylvania. A
structured, web-based survey was designed and administered
to surgeons who perform pancreatic surgery through 22 inter-
national gastrointestinal surgical societies. First, support
was engendered from several of the larger international gas-
trointestinal surgical societies, including the International
Hepato-Pancreato-Biliary Association (IHPBA), the Society for
Surgery of the Alimentary Tract (SSAT) and the Pancreas
Club. These organizations distributed the survey to their
extensive global memberships. Next, major regional associations
[the Americas Hepato-Pancreato-Biliary Association (AHPBA),
the Asian-Pacific Hepato-Pancreato-Biliary Association (A-
PHPBA), the European/African/Middle Eastern Hepato-Pancre-
ato-Biliary Association (E-AHPBA)] were targeted, as were
many of the national chapters under their respective purviews.
To facilitate global catchment, the e-surveys were made available
in eight different languages, including English, Chinese (i.e.
Mandarin), French, German, Italian, Japanese, Portuguese and
Spanish. Although the precise number of surgeons to whom the
survey was offered was not evident (some memberships over-
lapped across the various participating organizations), it is esti-
mated that this totalled 1500–2000 surgeons globally.
Surgeons initially indicated their region of practice. Geo-
graphical boundaries were established a priori as follows: North
America; South and Central America; Asia and Australia, and
Europe, Africa and the Middle East. Next, respondents were
asked to report any relevant fellowship training, as well as
other experience-related parameters, such as age, annual and
career volumes, and years of experience as an attending or staff
surgeon. The scope of the respondent’s current clinical practice
was also characterized.
Questions regarding the practice patterns of individual sur-
geons were presented using a modified Likert scale: (i) never,
0%; (ii) occasionally, 1–25%; (iii) sometimes, 26–75%; (iv) fre-
quently, 76–99%, and (v) always, 100%. Specific operative
techniques evaluated were pancreatogastrostomy (PG), dunk-
ing/invagination, isolated Roux limb, duct occlusion, anasto-
motic suturing preferences, trans-anastomotic stents,
autologous tissue patches, biological sealants (e.g. Tisseel, fibrin
glue), and placement of externalized drains. Management
decisions referred to the administration of prophylactic
somatostatin analogues (e.g. octreotide), and whether the sur-
geons practise early drain removal [postoperative day (PoD)
≤3] based upon drain amylase values.
Statistical analysis
Descriptive statistics are presented as frequencies for categorical
variables, and as the mean  standard deviation (SD) and
median [interquartile range (IQR)] for continuous variables.
Pearson’s chi-squared test or Fisher’s exact test, and indepen-
dent Student’s t-tests or analysis of variance (ANOVA) testing
were used to analyse categorical and continuous variables,
respectively. Non-parametric comparisons of continuous vari-
ables were assessed by Wilcoxon rank sum tests or Kruskal–
Wallis one-way ANOVA. P-values of ≤0.05 were considered to
indicate statistical significance. All tests were two-sided. Statis-
tical computations were performed utilizing IBM SPSS Statistics
for Windows Version 22.0 (IBM Corp., Armonk, NY, USA).
Results
Demographics and surgical experience
Surveys were completed by 897 surgeons, representing six conti-
nents and eight languages. Data fields were completed 98.9% of
the time. There were significant differences in the demographic
profile and experience of surgeons between regions (Table 1). A
total of 54.8% of surgeons described the scope of their clinical
practice as hepatopancreatobiliary (HPB) surgery, whereas just
3.6% said they practised pancreas surgery exclusively. Asian/Aus-
tralian surgeons were significantly more likely to have an HPB-
only practice compared with those in other regions (P < 0.001).
The median age and years of experience as an attending surgeon
were 45 years (IQR: 39–54 years) and 13 years (IQR: 6–
22 years), respectively. Within the last year, surgeons had per-
formed a median of 12 PDs (IQR: 6–25 PDs). Their median
cumulative career volume amounted to 80 PDs (IQR: 30–200
PDs); consequently, only 35.5% of responding surgeons were
considered to have a high-volume PD practice (i.e. ≥20 PDs per
year).10 This designation was most common in North America
(50.0%), and least common in South/Central America (8.0%).
Interestingly, only 53.8% of all surgeons had surpassed the learn-
ing curve for open PD, which has been reported to peak at 60
PDs.11 Nearly two-thirds of North American surgeons had
exceeded this threshold, compared with fewer than a quarter of
South American/Mexican surgeons (P < 0.001).
Operative approaches
Around a third of surgeons across the world use the same pan-
creatoenteric reconstruction in every case. Pancreatojejunos-
tomy (PJ) was the preferred anastomotic technique (88.7%)
(Table 2) and was favoured by 96.4% of North American sur-
geons. Conversely, PG was selected by less than one-tenth of
all respondents: European/African/Middle Eastern surgeons
demonstrated the greatest proclivity for this technique (16.5%;
P < 0.001). Isolated Roux limb reconstruction was uncommon
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in most regions, yet nearly a fifth of South American/Mexican
surgeons (16.8%) reported always using this approach. There
were also considerable degrees of variability between regions in
the suture types preferred for both inner and outer layers of
pancreatic anastomotic construction (P < 0.001 for each).
Surgeons were also asked a variety of questions regarding
the placement of trans-anastomotic stents (Table 3). Globally,
26.5% of surgeons never use stents, 57.4% use them selectively,
and 16.2% always employ them. Asian/Australian surgeons use
them most liberally. Stents of the external variety are always
employed by 2.1% of surgeons internationally; however, even
when avoiding absolutes, they are selected by only 17.5% of
surgeons. Short, internalized stents are used at least four times
as frequently as external stents across each region.
Other techniques used to putatively maintain the integrity of
the anastomosis include biological sealants and autologous
tissue patches. Globally, 34.9% of respondents turn to biologi-
cal sealants to augment the anastomotic connection. Similarly,
over a third (38.3%) use autologous tissue patches for rein-
forcement. The selective use of both strategies is most common
in North America.
Routine intraperitoneal drainage was reported by 59.2% of
surgeons, and this practice was most common in South/Central
America (71.2%). Across the world, only 26.9% of surgeons
drain selectively; North American and Asian/Australian sur-
geons demonstrated the greatest propensity for this approach.
In addition, significant variation exists around the world
regarding the types and numbers of drains used. Jackson–Pratt
Table 1 Demographics and experience of hepatopancreatobiliary (HPB) surgeons (n = 891*) by region
Variable Asia/Australia Europe/Africa/Middle East North America South/Central America Overall P-value
Surgeons, n (%) 209 (23.5%) 273 (30.6%) 282 (31.6%) 127 (14.3%) 891 –
Non-English survey
response, n (%)
15 (7.2%) 32 (11.7%) 0 86 (67.7%) 133 (14.9%) <0.001
Fellowship
training, n (%)
183 (87.6%) 203 (74.9%) 247 (88.2%) 113 (89.0%) 746 (84.1%) <0.001
Scope of clinical practice, n (%)
Pancreas only 5 (2.4%) 9 (3.3%) 14 (5.0%) 4 (3.1%) 32 (3.6%) <0.001
HPB 144 (69.2%) 166 (60.8%) 142 (50.4%) 36 (28.3%) 488 (54.8%)
Surgical oncology 15 (7.2%) 48 (17.6%) 76 (27.0%) 56 (44.1%) 195 (21.9%)
General surgery 31 (14.9%) 43 (15.8%) 42 (14.9%) 29 (22.8%) 145 (16.3%)
Other 13 (6.3%) 7 (2.6%) 8 (2.8%) 2 (1.6%) 30 (3.4%)
Age, years
Mean (SD) 47.0 (9.1) 47.0 (9.7) 48.0 (10.9) 43.9 (9.8) 46.9 (10.1) 0.002
Median (IQR) 46 (40–54) 46 (39–54) 47 (40–55) 42 (36–49) 45.0 (39–54) 0.001
Years of experience
Mean (SD) 15.5 (10.2) 14.4 (10.3) 13.9 (11.4) 14.5 (10.1) 14.6 (10.6) 0.404
Median (IQR) 15 (7–23) 14 (6–20) 11 (4–22) 13 (6–20) 13.0 (6–22) 0.118
PD volume
2013 calendar year
Mean (SD) 16.1 (16.4) 18.3 (16.7) 24.2 (22.4) 8.5 (8.2) 18.2 (l8.4) <0.001
Median (IQR) 12 (6–20) 15 (7–25) 19 (10–33) 6 (4–10) 12 (6–25) <0.001
Annual volume designation
≥20 (high-volume
surgeon)
62 (30.0%) 101 (38.0%) 136 (50.0%) 10 (8.0%) 309 (35.5%) <0.001
Career total number
of PDs
Mean (SD) 151.4 (220.5) 135.1 (165.9) 218 (277.7) 58.2 (80.4) 154.3 (218.0) <0.001
Median (IQR) 71 (35–200) 92.5 (31.5–200) 133 (36.25–300) 30 (17.25–61) 80 (30–200) <0.001
Surpassed the number of PDs required to surmount the learning curve, n (%)
≥50 139 (67.1%) 179 (67.3%) 194 (70.3%) 46 (36.5%) 558 (63.8%) <0.001
>60 110 (53.1%) 152 (57.1%) 178 (64.5%) 31 (24.6%) 471 (53.8%) <0.001
IQR, interquartile range; SD, standard deviation.
*Six surgeons did not indicate their region.
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Table 2 Utilization of operative strategies for pancreatoenteric reconstruction, stratified by region
Variable Asia/Australia Europe/Africa/
Middle East
North America South/Central
America
Overall P-value
Surgeons, n (%) 209 (23.5%) 273 (30.6%) 282 (31.6%) 127 (14.3) 891# –
Preferred anastomotic reconstruction
Pancreatojejunostomy 185 (88.5%) 221 (81.0%) 268 (96.4%) 111 (88.8%) 785 (88.7%) <0.001a
End-to-side duct-to-mucosa 133 (63.6%) 169 (61.9%) 220 (79.1%) 76 (60.8%) 598 (67.6%)
End-to-side invagination/
dunking
32 (15.3%) 35 (12.8%) 29 (10.4%) 10 (8.0%) 106 (12.0%)
End-to-end invagination/dunking 15 (7.2%) 7 (2.6%) 17 (6.1%) 20 (16.0%) 59 (6.7%)
End-to-end binding 5 (2.4%) 10 (3.7%) 2 (0.7%) 5 (4.0%) 22 (2.5%)
Pancreatogastrostomy 21 (10.0%) 45 (16.5%) 9 (3.2%) 11 (8.8%) 86 (9.7%)
Duct-to-mucosa 7 (3.3%) 7 (2.6%) 2 (0.7%) 5 (4.0%) 21 (2.4%)
Invagination/dunking 14 (6.7%) 38 (13.9%) 7 (2.5%) 6 (4.8%) 65 (7.3%)
No reconstruction (ductal
occlusion)
0 2 (0.7%) 1 (0.4%) 0 3 (0.3%)
Other 3 (1.4%) 5 (1.8%) 0 3 (2.4%) 11 (1.2%)
Same type of pancreatoenteric reconstruction on every case
No – variable according to the
circumstance of the case
66 (31.6%) 110 (40.4%) 87 (31.3%) 53 (42.1%) 316 (35.7%) 0.032
Yes – same technique
every time
143 (68.4%) 162 (59.6%) 191 (68.7%) 73 (57.9%) 569 (64.3%)
Suture technique
Single layer 48 (23.1%) 104 (38.1%) 30 (10.8%) 36 (28.6%) 218 (24.6%) <0.001
Double layer 160 (76.9%) 169 (61.9%) 249 (89.2%) 90 (71.4%) 668 (75.4%)
Suture type – if inner layer (duct-to-mucosa)
Absorbable monofilament (e.g.
PDS, Maxon, Monocryl)
154 (75.5%) 176 (68.5%) 221 (79.5%) 75 (59.5%) 626 (72.4%) <0.001
Absorbable braided (e.g. vicryl) 16 (7.8%) 13 (5.1%) 28 (10.1%) 16 (12.7%) 73 (8.4%)
Non-absorbable braided (e.g.
silk, polyester)
8 (3.9%) 24 (9.3%) 5 (1.8%) 8 (6.3%) 45 (5.2%)
Other (e.g. catgut, chromic) 6 (2.9%) 5 (1.9%) 12 (4.3%) 15 (11.9%) 38 (4.4%)
Do not perform an inner layer 20 (9.8%) 39 (15.2%) 12 (4.3%) 12 (9.5%) 83 (9.6%)
Suture type – if outer layer (pancreatic capsule-to-bowel)
Absorbable monofilament (e.g.
PDS, Maxon, Monocryl)
97 (46.9%) 136 (50.6%) 47 (17.0%) 40 (31.5%) 320 (36.4%) <0.001
Absorbable braided (e.g. vicryl) 14 (6.8%) 24 (8.9%) 33 (12.0%) 27 (21.3%) 98 (11.1%)
Non-absorbable braided (e.g.
silk, polyester)
69 (33.3%) 80 (29.7%) 178 (64.5%) 31 (24.4%) 358 (40.7%)
Other (e.g. catgut, chromic) 21 (10.1%) 10 (3.7%) 13 (4.7%) 27 (21.3%) 71 (8.1%)
I do not perform an
outer layer
6 (2.9%) 19 (7.1%) 5 (1.8%) 2 (1.6%) 32 (3.6%)
Pancreatogastrostomy
Never 128 (61.8%) 150 (56.2%) 185 (66.5%) 88 (69.8%) 551 (62.8%) 0.001
Occasionally (1–25%) 52 (25.1%) 65 (24.3%) 77 (27.7%) 28 (22.2%) 222 (25.3%)
Sometimes (26–75%) 9 (4.3%) 14 (5.2%) 8 (2.9%) 2 (1.6%) 33 (3.8%)
Frequently (76–99%) 12 (5.8%) 22 (8.2%) 4 (1.4%) 3 (2.4%) 41 (4.7%)
Always 6 (2.9%) 16 (6.0%) 4 (1.4%) 5 (4.0%) 31 (3.5%)
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drains are most common in North America (57.8%), whereas
Blake (51.8%) and Penrose (18.8%) drains are preferred in
South/Central America (P < 0.001). Of those surgeons who do
place drains, 60.7% place two. North Americans appeared
to take the least conservative approach and reported using a
single drain in 43.5% of patients. By contrast, only 19.6% of
Asian/Australian surgeons place a single drain.
Management decisions
In terms of management decisions, prophylactic somatostatin
analogues are never administered by 40.5% of the world’s
pancreatic surgeons and are always applied by just 13.6%. Sur-
geons from Asia/Australia and Europe/Africa/Middle East
favour this practice, the use of which is more infrequent in the
Americas. Another management approach involves early drain
removal (PoD ≤3) based upon drain amylase values. Early
drain removal is practised by 45.4% of surgeons who place
drains. North America is the only region in which fewer than
half of surgeons reported the use of this management strategy
(31.6%; P < 0.001). Globally, the median preferred PoD for
drain removal is PoD 5 (IQR: PoD 4–7).
Discussion
There appears to be significant heterogeneity in the demograph-
ics and practice patterns of PD surgeons around the world.
Globally, it is estimated that only around half of surgeons who
perform PD have carried out at least the number of PDs con-
sidered to facilitate completion of the full learning curve for
this procedure (>60 PDs),11 and, depending upon the region,
this figure may be as low as 25%. Furthermore, many contem-
porary operative and management options differ substantially
from those of evidence-based practice. Surgeons rarely utilize
the PG anastomotic technique and external trans-anastomotic
stents, and over two-thirds of surgeons in North America do
not practise early drain removal. Other notable trends include
the widespread use of techniques such as those involving the
use of biological sealants and autologous tissue patches that
have not been substantiated by any Level I evidence.
Tseng and colleagues performed a study in which they estab-
lished the first representation of the learning curve for PD.11
They reported that, after 60 cases, surgeons achieved significant
decreases in blood loss, operative time, and duration of hospi-
tal stay; additionally, the meeting of this threshold resulted in
more margin-negative resections. Applying this cut-off to the
current study showed that 53.8% of the overall cohort has sur-
passed the PD learning curve; therefore, according to this mea-
sure, nearly half of the world’s surgeons may be performing
PD with suboptimal intra- and postoperative outcomes.
The most recent work to establish and evaluate the impact
of annual volume and the PD learning curve was conducted by
Schmidt et al.10 Their study showed that high-volume surgeons
(≥20 PDs per year) had reduced operative time and intraopera-
tive blood loss, and also resected a significantly greater number
Table 2 Continued
Variable Asia/Australia Europe/Africa/
Middle East
North America South/Central
America
Overall P-value
Dunking or invagination
Never 86 (41.7%) 107 (39.9%) 94 (33.9%) 40 (32.5%) 327 (37.4%) 0.034
Occasionally (1–25%) 55 (26.7%) 80 (29.9%) 117 (42.2%) 41 (33.3%) 293 (33.5%)
Sometimes (26–75%) 10 (4.9%) 8 (3.0%) 14 (5.1%) 8 (6.5%) 40 (4.6%)
Frequently (76–99%) 32 (15.5%) 42 (15.7%) 27 (9.7%) 21 (17.1%) 122 (14.0%)
Always 23 (11.2%) 31 (11.6%) 25 (9.0%) 13 (10.6%) 92 (10.5%)
Duct occlusion
Never 192 (93.7%) 231 (88.5%) 255 (92.7%) 113 (91.9%) 791 (91.6%) 0.068
Occasionally (1–25%) 8 (3.9%) 26 (10.0%) 20 (7.3%) 6 (4.9%) 60 (6.9%)
Sometimes (26–75%) 3 (1.5%) 1 (0.4%) 0 3 (2.4%) 7 (0.8%)
Frequently (76–99%) 1 (0.5%) 2 (0.8%) 0 0 3 (0.3%)
Always 1 (0.5%) 1 (0.4%) 0 1 (0.8%) 3 (0.3%)
Isolated Roux limb
Never 152 (74.5%) 166 (62.6%) 227 (81.7%) 49 (39.2%) 594 (68.1%) <0.001
Occasionally (1–25%) 31 (15.2%) 57 (21.5%) 37 (13.3%) 31 (24.8%) 156 (17.9%)
Sometimes (26–75%) 4 (2.0%) 10 (3.8%) 3 (1.1%) 7 (5.6%) 24 (2.8%)
Frequently (76–99%) 9 (4.4%) 9 (3.4%) 6 (2.2%) 17 (13.6%) 41 (4.7%)
Always 8 (3.9%) 23 (8.7%) 5 (1.8%) 21 (16.8%) 57 (6.5%)
a
P < 0.001 even when comparing the condensed categorization of pancreatojejunostomy, pancreatogastrostomy, no reconstruction, and other.
#
Six surgeons did not indicate their region
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Table 3 Utilization of purported fistula mitigation strategies, stratified by region
Variable Asia/Australia Europe/Africa/
Middle East
North America South/Central
America
Overall P-value
Surgeons, n (%) 209 (23.5%) 273 (30.6%) 282 (31.6%) 127 (14.3%) 891 –
Trans-anastomotic stents
Never 37 (18.0%) 82 (30.1%) 73 (26.2%) 42 (33.1%) 234 (26.5%) <0.001
Occasionally (1–25%) 39 (18.9%) 74 (27.2%) 73 (26.2%) 41 (32.3%) 227 (25.7%)
Sometimes (26–75%) 23 (11.2%) 38 (14.0%) 32 (11.5%) 12 (9.4%) 105 (11.9%)
Frequently (76–99%) 40 (19.4%) 48 (17.6%) 67 (24.0%) 20 (15.7%) 175 (19.8%)
Always 67 (32.5%) 30 (11.0%) 34 (12.2%) 12 (9.4%) 143 (16.2%)
Type of stent used
Internal 112 (67.5%) 135 (71.8%) 156 (75.7%) 56 (65.9%) 459 (71.2%) 0.064
External 34 (20.5%) 42 (22.3%) 27 (13.1%) 17 (20.0%) 120 (18.6%)
Depends on the case 20 (12.0%) 11 (5.9%) 23 (11.2%) 12 (14.1%) 66 (10.2%)
Biological sealants
Never 140 (68.0%) 174 (64.0%) 176 (63.3%) 84 (66.7%) 574 (65.1%) 0.007
Occasionally (1–25%) 32 (15.5%) 62 (22.8%) 62 (22.3%) 27 (21.4%) 183 (20.7%)
Sometimes (26–75%) 7 (3.4%) 16 (5.9%) 15 (5.4%) 10 (7.9%) 48 (5.4%)
Frequently (76–99%) 9 (4.4%) 12 (4.4%) 17 (6.1%) 5 (4.0%) 43 (4.9%)
Always 18 (8.7%) 8 (2.9%) 8 (2.9%) 0 34 (3.9%)
Autologous tissue patches
Never 134 (64.4%) 172 (64.2%) 147 (53.1%) 89 (71.2%) 542 (61.7%) 0.001
Occasionally (1–25%) 34 (16.3%) 51 (19.0%) 52 (18.8%) 21 (16.8%) 158 (18.0%)
Sometimes (26–75%) 18 (8.7%) 18 (6.7%) 20 (7.2%) 5 (4.0%) 61 (6.9%)
Frequently (76–99%) 10 (4.8%) 12 (4.5%) 38 (13.7%) 7 (5.6%) 67 (7.6%)
Always 12 (5.8%) 15 (5.6%) 20 (7.2%) 3 (2.4%) 50 (5.7%)
Prophylactic, intraperitoneal drainage
Never 26 (12.6%) 47 (17.2%) 41 (14.7%) 9 (7.2%) 123 (13.9%) 0.003
Occasionally (1–25%) 25 (12.1%) 19 (7.0%) 26 (9.3%) 14 (11.2%) 84 (9.5%)
Sometimes (26–75%) 8 (3.9%) 11 (4.0%) 18 (6.5%) 2 (1.6%) 39 (4.4%)
Frequently (76–99%) 28 (13.5%) 27 (9.9%) 49 (17.6%) 11 (8.8%) 115 (13.0%)
Always 120 (58.0%) 169 (61.9%) 145 (52.0%) 89 (71.2%) 523 (59.2%)
Type of drain(s) regularly used
Jackson–Pratt 65 (36.7%) 74 (33.5%) 134 (56.5%) 21 (18.3%) 294 (39.2%) <0.001
Blake 53 (29.9%) 61 (27.6%) 94 (39.7%) 58 (50.4%) 266 (35.5%)
Penrose 21 (11.9%) 36 (16.3%) 1 (0.4%) 21 (18.3%) 79 (10.5%)
Other 37 (20.9%) 50 (22.6%) 3 (1.3%) 12 (10.4%) 102 (13.6%)
Number of drain(s) regularly used
1 35 (19.6%) 56 (25.8%) 101 (43.5%) 28 (24.3%) 220 (29.6%) <0.001
2 119 (66.5%) 131 (60.4%) 121 (52.2%) 80 (69.6%) 451 (60.7%)
≥3 18 (10.1%) 22 (10.1%) 5 (2.2%) 5 (4.3%) 50 (6.7%)
Varies each case 7 (3.9%) 8 (3.7%) 5 (2.2%) 2 (1.7%) 22 (3.0%)
Remove drains based on early (PoD ≤3) drain amylase values
No 84 (46.4%) 112 (49.6%) 160 (68.4%) 56 (49.1%) 412 (54.6%) <0.001
Yes 97 (53.6%) 114 (50.4%) 74 (31.6%) 58 (50.9%) 343 (45.4%)
Preferred PoD drain removal,
median (IQR)
5 (5–7) 5 (4–7) 5 (4–6) 7 (5–8) 5 (4–7) <0.001
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of lymph nodes. Data for these surgeons also showed a trend
towards lower rates of overall morbidity and mortality. In the
current study, just 35.5% of surgeons met this criterion; in
only a single region – North America – did the PD volume of
>38% of surgeons surpass this cut-off.
Schmidt et al.10 defined experienced surgeons as those with a
career PD volume of ≥50 PDs; these surgeons were associated
with significantly lower rates of overall morbidity, pancreatic
leaks as defined by the International Study Group on Pancreatic
Fistula (ISGPF), operative time, and mean intraoperative blood
loss. Only 63.8% of surgeons in the present study met this
criterion for the ‘experienced surgeon’, and as few as 36.5% of
surgeons in South/Central America did so. Similar proportions
of surgeons from each of the other three regions were found to
have surpassed this cut-off (67.1–70.3%). A more refined
approach within the work of Schmidt et al.10 evaluated the
number of PDs necessary for less experienced surgeons (<50
PDs) to achieve outcomes numerically equivalent to those
obtained by experienced surgeons (≥50 PDs). Interestingly,
these authors10 considered that the performance of 60 PDs –
the value derived by Tseng et al.11 –was necessary for less expe-
rienced surgeons to achieve equivalent mortality rates.
Randomized controlled trials conducted during the contem-
porary ISGPF era have enabled unbiased comparisons of many
intraoperative techniques and management options. One such
comparison refers to the technique used for pancreatic anasto-
motic reconstruction. Meta-analyses of contemporary RCTs
have concluded that the PG anastomotic technique is superior
to PJ.1,12,13 In an investigation of seven recent RCTs, Liu
and colleagues reported that PG was associated with lower rates
of clinically relevant pancreatic fistula, biliary fistula and intra-
abdominal collections.12 Furthermore, PG correlated positively
with reduced hospital stay. Despite the preponderance of evi-
dence suggesting the superiority of PG to PJ, the current study
demonstrated that less than 10% of world surgeons prefer PG,
whereas PJ is the anastomotic technique of choice for the over-
whelming majority (88.7%). Stratification by region shows that
PG is the primary choice for only 3.2% of North American sur-
geons, but is preferred by 16.5% of European/African/Middle
Eastern surgeons. This may reflect a regional bias because every
contemporary RCT establishing improved outcomes with PG
has been conducted in either Europe14–19 or the Middle East.20
Another operative issue of interest concerns the placement
of trans-anastomotic stents. A recent meta-analysis of RCTs
found external stents – versus no stents – to decrease the inci-
dence of pancreatic fistula, lower overall morbidity and reduce
the duration of hospital stay.21 The rationale for external stent-
ing includes the facilitation of precise suture placement, as well
as the ability to divert or shunt proteolytic enzymes from the
anastomotic site.22 Although meta-analyses of contemporary
RCTs demonstrate a benefit of external stents,2,21 only 2.1% of
international surgeons always use them. Even when avoiding
absolutes, <20% of world surgeons selectively or always employ
this technique. As with PG, there appears to be a trend
towards regional bias; two23,24 of the three recent RCTs report-
ing a benefit of external stenting were performed in Asian
countries and none originated in North America. Conse-
quently, Asian/Australian surgeons are most likely to use exter-
nal stents selectively or always (22.5%), and North Americans
are least likely to use external stents (17.7%). Perhaps even
more notably, although Level I evidence suggests there is no
difference in outcomes between cases in which internal stents
are used and those in which no stents are used,25 internal
stents are utilized selectively or always by 57.7% of world PD
surgeons.
The present study also evaluated the use of biological sea-
lants, which are haemostatic agents used to augment the anas-
tomotic connection. Biological sealants have been tested in two
RCTs,3,4 neither of which reported lower rates of anastomotic
leak or complications with sealants. Despite these negative
findings, the current study demonstrated that 34.9% of sur-
geons use biological sealants selectively or always. The contin-
ued use of sealants – despite the lack of apparent benefit – is
particularly surprising when cost is considered. In 2004, a ran-
domized trial by Lillemoe and colleagues reported the cost of
fibrin glue to be US$328 per patient.3 The administration of
fibrin glue in every PD patient at a high-volume centre, such
as Johns Hopkins Hospital (Baltimore, MD, USA), where
approximately 300 PDs are performed per year, would cost
approximately US$98 400 per year.
Another operative technique for reinforcing the pancreatic
anastomosis concerns the use of autologous tissue patches. In
this approach, the round ligament of the liver is detached from
the abdominal wall and attached circumferentially at the PJ
Table 3 Continued
Variable Asia/Australia Europe/Africa/
Middle East
North America South/Central
America
Overall P-value
Prophylactic somatostatin analogues
Never 63 (30.3%) 78 (28.7%) 152 (54.7%) 65 (51.2%) 358 (40.5%) <0.001
Occasionally (1–25%) 42 (20.2%) 54 (19.9%) 72 (25.9%) 31 (24.4%) 199 (22.5%)
Sometimes (26–75%) 26 (12.5%) 48 (17.6%) 23 (8.3%) 15 (11.8%) 112 (12.7%)
Frequently (76–99%) 30 (14.4%) 37 (13.6%) 17 (6.1%) 12 (9.4%) 96 (10.8%)
Always 47 (22.6%) 55 (20.2%) 14 (5.0%) 4 (3.1%) 120 (13.6%)
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anastomosis.26 Thus far, evaluations of the efficacy of this prac-
tice in PD are limited to one retrospective review.26 Although
no Level I evidence supports this practice for PD, 38.3% of the
world’s PD surgeons employ this technique selectively or
always. Support for this practice is particularly pronounced in
North America, where nearly half of surgeons (46.9%) attest to
using this approach selectively or always in PD.
Externalized intraperitoneal drains have traditionally accom-
panied PD. Recently, routine drainage was assessed in a random-
ized setting; results demonstrated that routine drainage was
associated with fewer and less severe complications.5 A sec-
ondary endpoint of that study referred to the specific investiga-
tion of the impact of drainage on the incidence of pancreatic
fistula6 and found that patients with negligible or low risk for the
development of fistula (according to the Fistula Risk Score27) do
not require drains, whereas those with moderate or high risk for
fistula benefit from drain placement. Although that study6 con-
cluded that selective drainage was beneficial, the present study
demonstrates that only 26.9% of the world practises selective
drainage; furthermore, 13.9% of PD surgeons never place a drain
prophylactically, regardless of the patient’s degree of risk.
Another management decision involves the PoD of drain
removal. A contemporary, randomized trial by Bassi and col-
leagues evaluated the efficacy of early drain removal based upon
PoD 1 drain amylase values.28 The authors reported that early
drain removal was associated with significantly lower rates of
pancreatic fistula, abdominal complications and pulmonary
complications.28 Despite these findings, the current study
demonstrates that less than half (45.4%) of the surgeons surveyed
remove drains based on early (PoD ≤3) drain amylase values.
This discordance with Level I evidence was particularly pro-
nounced in North America, where fewer than a third (31.6%) of
surgeons follow this practice; conversely, European/African/Mid-
dle Eastern and Asian/Australian surgeons take this approach in
50.4% and 53.6% of cases, respectively. This may once again
reflect regional biases. The first major prospective trial to demon-
strate a benefit of early drain removal was conducted by Kawai
et al. in Japan,29 and the only randomized trial to address this
topic was conducted in Verona, Italy.28 Notably, no randomized
trials to date have scrutinized this practice in North America.
One of the more contentious management issues upon
which pancreatic surgeons must make decisions regards the
administration of prophylactic somatostatin analogues, such as
octreotide. At least eight high-volume (>100 patients) RCTs
have investigated the use of octreotide with inconclusive find-
ings.30 However, much of this incongruence can be attributed
to the evolution of nomenclature for postoperative complica-
tions. For example, before the advent of the ISGPF nomencla-
ture for fistulae, studies did not differentiate between the
incidence of innocuous biochemical (Grade A) and clinically
relevant (Grades B and C) fistulae. Since the emergence of the
ISGPF, no high-volume, randomized trials have found octreo-
tide to be associated with lower rates of clinically relevant
fistula; however, the largest retrospective study to evaluate
octreotide showed it to be associated with a reduced incidence
of biochemical fistula and, in fact, higher rates of clinically rel-
evant fistula.30
In the present study, the prevalence of somatostatin ana-
logue utilization appeared to correlate with the regional loca-
tions – as well as the findings – of randomized trials.
European/African/Middle Eastern surgeons selectively or always
administer prophylactic somatostatin analogues 71.3% of the
time and the first four randomized trials to associate octreotide
with improved outcomes were conducted at European centres.
By contrast, only 45.3% of North American surgeons adminis-
ter somatostatin analogues selectively or always; this may reflect
the inconclusive findings regarding the efficacy of octreotide in
high-volume, randomized North American studies. A recent
study conducted by surgeons at the Memorial Sloan–Kettering
Cancer Center investigated the new somatostatin analogue,
pasireotide, and reported that it was associated with a decreased
rate of clinically significant pancreatic fistula; however, pasireo-
tide has not been evaluated in a multicentre setting.31 Overall,
the literature regarding this approach is inconclusive and its
administration seems to be heavily influenced by the geographi-
cal location of relevant randomized studies.
There are several noteworthy limitations to this study. Firstly,
it relied on surgeons’ self-reports of their experience and practice
patterns. The possibility that surgeons may have exaggerated
their annual and career volumes of PD emphasizes how few sur-
geons have actually surpassed the quantity of PDs considered
necessary to surmount the learning curve and qualify as a high-
volume surgeon. Secondly, as expected, missing responses were
occasionally encountered, although approximately 99% of the
data fields were completed. As this study was heavily focused on
investigating approaches that may influence pancreatic fistula
development, some operative techniques were not explored (e.g.
pylorus-preserving versus classical PD). Furthermore, given the
study’s inability to establish a firm denominator, the degree to
which this reflects global practice cannot be definitively ascer-
tained. Additionally, this study exclusively surveyed members of
surgical societies, which limits the full extent of its reach. Lastly,
this study’s descriptive nature does not allow the direct linkage
of surgical volume and practice patterns to actual outcomes.
In summary, this study defined the demographics and prac-
tice patterns of surgeons performing PD around the world by
examining surgeons who are members of gastrointestinal and
oncologic surgical societies. Surprisingly low annual and career
volumes were reported, which may explain the significant
heterogeneity in the morbidity and mortality rates published
throughout the surgical literature. This study also demonstrated
considerable variation in operative and management decisions,
underscoring the numerous options available to surgeons who
perform this operation. Many of these choices contrast with
established randomized evidence, and this incongruence is par-
ticularly stark in regions in which a practice either has not been
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tested or has produced alternative findings in a randomized set-
ting. It may be that personal habits or institutional and training
influences play a role in explaining why the clinical practice of
many surgeons has not evolved to fall in line with the highest-
level evidence. It remains to be seen whether the standardiza-
tion of these diverse clinical practices may lead to improved, or
more consistent, outcomes. Thus, the findings presented here
may have implications on the design of future trials regarding
operative and management strategies in PD.
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